Zentalis Pharmaceuticals
ZNTL
102 hedge funds and large institutions have $102M invested in Zentalis Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 10 closing their positions.
604% more call options, than puts
Call options by funds: $971K | Put options by funds: $138K
170% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 10
85% more capital invested
Capital invested by funds: $54.9M → $102M (+$46.8M)
19% more funds holding
Funds holding: 86 → 102 (+16)
5.23% more ownership
Funds ownership: 56.18% → 61.41% (+5.2%)
7% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 28
Top Buyers
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$2.44M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.42M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.34M |
| 4 |
Morgan Stanley
New York
|
-$1.17M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$683K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Wells Fargo
San Francisco,
California
| $1 | +$3 | +1 | New |
|
102
Two Sigma Advisers
New York
| – | -$2M | -1,483,500 | Closed |
|
103
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$168K | -124,525 | Closed |
|
104
Walleye Capital
New York
| – | -$149K | -110,448 | Closed |
|
|
OC
105
Opal Capital
Boca Raton,
Florida
| – | -$173K | -72,251 | Closed |
|
|
AG
106
Algert Global
San Francisco,
California
| – | -$65K | -48,496 | Closed |
|
|
AWA
107
Acorn Wealth Advisors
Grand Blanc,
Michigan
| – | -$27K | -20,000 | Closed |
|
108
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$32.6K | -12,642 | -99% |
|
|
IC
109
IEQ Capital
Foster City,
California
| – | -$16.5K | -12,229 | Closed |
|
|
HWP
110
Highline Wealth Partners
Sherman Oaks,
California
| – | -$6.75K | -5,000 | Closed |
|
|
CIAM
111
Caitong International Asset Management
Hong Kong
| – | -$1 | -1 | Closed |
|
ZNTL Hedge Fund Activity: Q1 2026 in Review
102 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2026, worth a combined $102M — up 85% from $54.9M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ZNTL positions and 10 closed out — a net gain of 17 holders — while 30 added to existing stakes and 28 trimmed.
The largest buyer was Squadron Capital Management, opening a new position worth an estimated $9.38M. The largest seller was Renaissance Technologies, cutting an estimated $2.44M.
- 102 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2026, up from 86 in Q4 2025.
- Funds reported $102M of Zentalis Pharmaceuticals stock for Q1 2026, up 85% quarter-over-quarter.
- 27 funds opened new Zentalis Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
- The largest Zentalis Pharmaceuticals buyer in Q1 2026 was Squadron Capital Management, an estimated $9.38M added.
- The largest Zentalis Pharmaceuticals seller in Q1 2026 was Renaissance Technologies, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2026.